Suppr超能文献

在一家三级保健医疗中心开发一种评分系统,用于鉴定具有测序能力的细菌广谱 16S rRNA 基因 PCR 的高产量标本。

Development of a scoring system to identify high-yield specimens for bacterial broad-range 16S rRNA gene PCR with sequencing at a tertiary care medical center.

机构信息

Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, Washington University, St Louis, MO, US.

Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US.

出版信息

Am J Clin Pathol. 2023 Nov 2;160(5):477-482. doi: 10.1093/ajcp/aqad074.

Abstract

OBJECTIVES

Broad-range bacterial polymerase chain reaction with sequencing (BRBPS) provides valuable diagnostic data, especially in cases of culture-negative infections. However, as BRBPS testing demonstrates generally low positivity, cost per impactful result can be high and commonly involves longer turnaround times compared with other methods, targeting use of this assay to high-yield situations remains a challenging goal. Diagnostic stewardship can help alleviate these challenges and increase clinical utility, yet not all laboratories have a dedicated stewardship team, and little formal guidance exists on identifying high-yield samples outside of specific clinical syndromes. In this study, we performed a retrospective review of 86 BRBPS orders from a tertiary care medical center, with a focus on identifying high-yield cases using an infectious markers scoring system, visualized inflammation or organism (VIO) score, to predict return of actionable diagnostic data.

METHODS

Using chart review, we evaluated how results from high VIO score or low VIO score specimens contributed to clinical management.

RESULTS

Testing low VIO score samples identified an organism in only 10% of samples, and of these positive results, 33% were considered to represent contamination. Despite negative routine workup and no identified pathogen via BRBPS, broad antimicrobial treatment was continued in 85% of cases with a low VIO score. In contrast, specimens with high VIO scores were more predictably positive by BRBPS, identified organisms that were universally considered pathogens, and provided opportunities to target or de-escalate antimicrobial therapy.

CONCLUSIONS

This study describes the VIO scoring system to guide the identification of high-yield samples and steward the appropriate use of BRBPS testing.

摘要

目的

广谱细菌聚合酶链反应测序(BRBPS)提供了有价值的诊断数据,尤其是在培养阴性感染的情况下。然而,由于 BRBPS 检测的阳性率通常较低,每个有影响结果的成本可能很高,与其他方法相比,通常需要更长的周转时间,因此,将这种检测方法用于高产量的情况仍然是一个具有挑战性的目标。诊断管理有助于缓解这些挑战并提高临床实用性,但并非所有实验室都有专门的管理团队,并且针对特定临床综合征之外的高产量样本,很少有正式的指导意见来确定。在这项研究中,我们对一家三级保健医疗中心的 86 份 BRBPS 订单进行了回顾性审查,重点是使用感染标志物评分系统(VIO 评分)确定高产量病例,以预测可采取行动的诊断数据的回报。

方法

通过图表审查,我们评估了高 VIO 评分或低 VIO 评分标本的结果如何有助于临床管理。

结果

对低 VIO 评分样本的检测仅在 10%的样本中发现了一种病原体,而这些阳性结果中,有 33%被认为是污染。尽管常规检查结果为阴性,且通过 BRBPS 未发现病原体,但仍有 85%低 VIO 评分的病例继续接受广泛的抗菌治疗。相比之下,VIO 评分高的标本通过 BRBPS 更可预测地呈阳性,鉴定出普遍被认为是病原体的病原体,并提供了靶向或降级抗菌治疗的机会。

结论

本研究描述了 VIO 评分系统,以指导高产量样本的识别,并管理 BRBPS 检测的合理使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验